The B-cell lymphoma 2 (BCL-2) protein family is pivotal in maintaining the balance between cell survival and apoptosis. BCL-2, the founding member of this family, is an anti-apoptotic protein that inhibits the release of cytochrome c from the mitochondria, thereby preventing the activation of caspase-dependent apoptosis. During aging, dysregulation of BCL-2 and its pro-apoptotic counterparts can lead to the accumulation of senescent cells and the development of age-related diseases. BCL-2 expression is often upregulated in senescent cells, contributing to the persistence of the senescence-associated secretory phenotype (SASP), which promotes inflammation and tissue damage.
Fig. 1 Bcl-2 family members act upstream of mitochondrial-mediated apoptosis. (Zhu Y, et al., 2016)
CD BioSciences is committed to helping clients understand the role of BCL-2 in aging and developing anti-aging drugs that target this critical pathway.
How Do We Identify BCL-2 as an Anti-Aging Target?
Our expertise in cellular and molecular biology allows us to help clients investigate the role of the BCL-2 signaling pathway in aging. We help clients determine the expression levels of BCL-2 and its family members in senescent cells. Utilizing RNA interference (RNAi) technologies, CD BioSciences can systematically evaluate the role of BCL-2 in cellular senescence and the aging process.
How Do We Develop Anti-Aging Drugs Targeting BCL-2?
CD BioSciences offers a comprehensive suite of services for discovering and developing senolytic drugs that target the BCL-2 signaling pathway, which can selectively induce apoptosis in senescent cells. We help clients customize cellular senescence models to evaluate the efficacy of potential senolytic drugs, performing qPCR and Western blotting to assess changes in BCL-2 expression. Additionally, we help clients assess the impact of drug candidates on age-related diseases and overall lifespan in vivo.
How Do We Evaluate Anti-Aging Drugs Targeting BCL-2 in Preclinical Animal Models?
We employ a robust preclinical evaluation process to analyze the efficacy of senolytic drugs targeting the BCL-2 signaling pathway. We offer preclinical animal models that allow clients to assess the effects of senolytic drugs on lifespan and the treatment of aging-related diseases.
Pharmacokinetic and pharmacodynamic services
We help clients conduct comprehensive pharmacokinetic and pharmacodynamic analyses to determine the senolytic drug concentration required for anti-aging effects.
Histopathological and molecular analysis services
CD BioSciences offers detailed histological and molecular analyses of tissues to evaluate the effects of senolytic drugs targeting BCL-2 on senescent cell populations.
Omics services
We employ omics technologies, such as transcriptomics and proteomics, to help clients understand the changes induced by senolytic drugs. We help clients identify novel biomarkers and pathways involved in the aging process, providing insights into the potential of senolytic drugs.
CD BioSciences is dedicated to advancing the field of anti-aging drug discovery through the targeted inhibition of the BCL-2 pathway. Our comprehensive approach to preclinical evaluation, supported by reliable technologies and animal models, helps the development of effective anti-aging drugs. If you are interested in our services, please feel free to contact us or make an online inquiry.
Reference
- Zhu Y, et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell, 2016, 15 (3): 428-35.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
